Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Completed
National Cancer Institute (NCI)
Phase 3
1994-10-01
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens
can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide,
goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens.
It is not yet known which regimen of antiandrogen therapy is most effective for prostate
cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or
without antiandrogen therapy in treating patients who have stage I or stage II prostate
cancer.
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Completed
Radiation Therapy Oncology Group
Phase 3
1994-10-01
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens
can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide,
goserelin, and leuprolide may fight prostate cancer by reducing the production of androgens.
It is not yet known which regimen of antiandrogen therapy is most effective for prostate
cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or
without antiandrogen therapy in treating patients who have stage I or stage II prostate
cancer.
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
Completed
National Cancer Institute (NCI)
Phase 3
1996-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining hormone therapy with chemotherapy and androgen
suppression may kill more tumor cells. It is not yet known which treatment regimen is more
effective for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone
therapy versus androgen suppression alone as initial therapy in patients with prostate cancer
that is metastatic or that cannot be removed surgically.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
